

FIGURE 1: VITAMIN D SUPPLEMENTATION EVIDENCE



Green Text = consistent evidence from high quality meta-analyses or RCTs

Yellow Text = evidence from RCTs or lower-quality meta-analyses

Orange Text = evidence from observational studies, or RCT evidence with limitations or inconsistency

Pink Text = lack data

This figure does not include health conditions where a correlation has been observed with Vitamin D levels but not yet tested with Vitamin D supplementation (these are outlined in Table 2).

Vitamin D: Therapeutic Overview & Evaluation of Evidence for Current Claims ^{1,2,3,4}

Vitamin D deficiency in Canada ⁵ (see Table 1 below for significance of level)	○ Statistics Canada: 32% of Canadians have levels < 50nmol/L (25% in summer, 40% in winter), and 10% are < 30 nmol/L ^{(mean overall 64nmol/L)⁴²}
⇒Symptoms	○ muscle weakness, bone pain
⇒Risk factors	○ dark skin , lack of sunlight (northern latitude, atmospheric pollution), sunscreen use (however, sunscreen use is recommended to reduce skin cancer risk), occlusive clothing, elderly, obese or institutionalized, malabsorption (e.g. inflammatory bowel disease, celiac disease), renal disease, medications (anticonvulsants, thiazides, ²⁰ corticosteroids, antiretrovirals (HIV), cholestyramine, rifampin)
Types of vitamin D	○ vitamin D3 or cholecalciferol: (preferred form) synthesized normally in the skin via 7-dehydrocholesterol {1000IU of D3 daily will increase 25(OH)D levels by ~15-25nmol/L ⁶ over 8 months} ○ vitamin D2 (or ergocalciferol) a plant based derivative; option for vegans; no longer considered bioequivalent to vitamin D3 ○ calcitriol : one of the active forms of Vit D in the body is calcitriol: used in patients with end-stage renal disease (ESRD) who are unable to convert vit D3 to calcitriol
⇒Supplements available in Canada Vitamin D2 and D3 most useful in primary care; other analogues used in specialized areas such as chronic kidney disease.	○ vitamin D3: OTC: 400IU, 1,000 IU tabs Rx: 2,000 IU cap, 5,000 IU cap, 10,000 IU cap/tab; 25,000 IU cap, 50,000 IU cap, 50,000-75,000 IU manufactured cap ^{from powder} ○ vitamin D3: OTC: D-VI-SOL 400 IU/ml, DDROPS (600 or 1000 units/drop^{5ml=180drops}) liquid; OTC Peds: BABY DDROPS : 400 units/drop^{~\$20 / 2.5ml bottle (~ 90 drops)} ○ vitamin D2 Rx: OSTO-D2, D-FORTE 50,000 IU/cap ○ calcitriol Rx: ROCALTROL, generics: 0.25ug, 0.5ug cap (expensive) ○ other ^{expensive} Rx: alfacalcidol ONE-ALPHA 0.25 ug, 0.5 ug, 1 ug cap, 2 ug/mL
Dosage Guidelines/Considerations	○ Osteoporosis Canada guidelines ⁶ : ● adults <50 yrs at low risk for deficiency: vitamin D3 400-1,000 IU once daily ● adults ≥ 50yrs & moderate-high risk : vitamin D3 800-2,000 IU once daily - up to 2,000 IU/day considered safe without requiring medical supervision Max: Vit D from all sources 4000IU/day for all older adults recommended by the American Geriatrics Society 2013 and IOM 2010} ● adults in long-term care : vitamin D3 800-2,000 IU once daily {if high fracture risk, strongly recommended, otherwise dep. on values/pref/resources} ⁴⁶ ○ Canadian Cancer Society ⁷ ● adult (during fall & winter): 1,000 IU/day ● older adults, dark skin or little sun exposure: 1,000 IU/day all year ○ Canadian Pediatric Society ⁸ : ● pregnancy & lactation : consider 2,000 IU daily especially during the winter ● breastfed infants : 400 IU/day; 800 IU/day for northern Native communities ^(especially in winter) ● formula fed : no supplement needed; except Northern communities 400 IU/day ^{from Oct –Apr} ○ Scientific Advisory Committee on Nutrition (SACN, UK) ⁴⁵ : ≥4 years: 400 IU once daily ○ IOM 2010 : Recommended dietary allowance ≥1yr = 600IU/day, if ≥71yr = 800IU/day
Maintenance Range: ◆ 400 IU - 2,000 IU daily ◆ Evidence supports efficacy & safety of 800 – 2,000 IU/day for most and possibly up to the daily upper limit of 4,000 IU, especially in high risk & in winter. (some suggest Vit D3 10,000 IU weekly or Vit D2 50,000 IU monthly to ↓ pill burden) ⁶	○ lack of evidence and highly variable in literature and clinical practice ○ approaches vary: {D3 used more than D2; daily ^{9,10} e.g. 2,000 – 4,000 IU daily x 8-20 weeks; weekly ^{11,12} e.g. 50,000 weekly x 8 wks (Vit D2 trials); monthly e.g. 50,000 monthly x 9; or single bolus 10,000 - 150,000 IU x1 } may depend on starting 25(OH)D level, BMI, effective sun exposure & other factors ^{eg. malabsorption} ○ single yearly high doses (500,000 IU orally or 300,000 IU IM) are not recommended in the elderly due to increased risk of fracture +/- fall esp. in the first few months post dose; ^{13,14} if used, vitamin D3 is preferred over vitamin D2. ⁴⁷
Unit Conversion: 400 IU = 10 mcg (1mcg = 40 IU) 800 IU = 20 mcg 1000 IU = 25 mcg 2000 IU = 50 mcg	○ hypercalcemia ¹⁵ , hypercalciuria ○ GI symptoms (may be due to combination with Ca ⁺⁺ intake) ¹⁶ ○ renal disease, nephrolithiasis [400 IU/day + Ca ⁺⁺ (~2,100mg/day ^{total avg intake}) HR=1.17 ^{WHI - 7yrs}] ³⁹ ○ increased fall & fracture rates with very high single yearly doses of 500,000 IU oral vitamin D3 ¹⁴ , & similar increases in fractures (not falls) with 300,000 IM yearly. ¹⁵
Vitamin D Bolus doses ◆for severe deficiency ◆may consider initial bolus if serum 25(OH)D level is <25-50nmol/L followed by maintenance	○ fish: salmon, sardines, tuna & mackerel (200–600 IU/3.5-oz serving) ³ & fish oils ○ small amounts found in beef liver, cheese and egg yolks ○ some mushrooms may contain varying amounts of vitamin D2 ○ fortified food sources such as fortified milk/orange juice (8oz glass = 100 IU)
Vitamin D adverse effects	○ Extras: appropriate vitamin D levels may improve absorption of dietary calcium from 10-15% up to 30-40% ^{3,18}
Food sources ¹⁷ {Difficult to get adequate Vit D from dietary sources alone; whereas it is possible to get adequate calcium from diet alone.}	

Table 1: Classification of 25-hydroxyvitamin D (25(OH) D) serum levels * (ng/ml x 2.496 = nmol/L)

25(OH)D (nmol/L)	< 30 ^{20,42}	30-50 ^{20,42,43}	50 – 125 ^{43,44}	>125 ^{43,44}	> 375 – 500 ⁴⁵
	Osteomalacia/rickets deficiency	Poor bone health insufficiency/suboptimal	Optimal bone health	Potential adverse effects	Toxic

*Levels ◆ **not** routinely recommended; useful if high risk of vitamin D deficiency or toxicity concerns.^{6, 19,112,113} Cost: \$20-60
 ◆ **IOM 2010**: ≥50 nmol/L adequate level (some controversy with US Endocrine Society recommending 75 nmol/L)¹¹⁰
 ◆ 1000IU/day of D3 will increase 25(OH)D levels by ~15-25nmol/L^{6,20} over 8 months

Table 2: Claims and Evidence for Vitamin D (Abridged; for discussion, see reference link to detailed trials summary table ²¹)

www.RxFiles.ca

Category	Claims	Evidence
Skeletal	Prevents hip fractures and mortality ^{16,22,48-53}	<p>Falls/fractures (per 1,000 treated)*:^{48, 49 (CADTH umbrella review), 50-53}</p> <ul style="list-style-type: none"> ◆ 5 fewer hip # (95%CI 2-8) ◆ No change in fall risk¹¹¹ ◆ 7 fewer deaths (95%CI1-14) <p>CADTH umbrella review of 5 meta-analyses (elderly long-term care population): fall risk only reduced in 1 meta-analysis; others showed no benefit.⁴⁹</p> <p>* Benefits only seen when used with Ca⁺⁺. Subgroups with more benefit: low vitamin D levels, community-dwelling elderly under 80 with no cognitive impairment, no Hx of fall/fracture.</p> <p>Toxicities for every 1,000 patients:⁴⁸⁻⁵³</p> <ul style="list-style-type: none"> ◆ 8 more GI AE ◆ ?5 more hypercalcemia ◆ 3 more renal insufficiency or calculi ◆ 23 more MI <p>* Most harms related to Ca⁺⁺ component. Limit Ca⁺⁺ to max 500 mg/day (elemental).</p> <p>Functional decline:²³</p> <p>Higher doses (60,000 or 24,000 IU monthly) had more falls than the 24,000 IU monthly group. No benefit on lower extremity function.</p> <p>Single dose resulted in an increase in fracture +/- fall within the first 3 months after initial dose¹⁵</p> <ul style="list-style-type: none"> ◆ No adverse effects noted below 200,000 IU yearly in another large-dose study (300,000-600,000 IU po yearly)⁴⁷
	Does not prevent falls ^{23, 24,48-53}	
	Slightly increases femoral neck mineral density ⁵⁴	<ul style="list-style-type: none"> ◆ 0.8% increase at femoral neck (95%CI 0.2-1.4%, with heterogeneity among trials) ◆ No effect at other sites⁵⁴
	Steroid induced osteoporosis: Increases lumbar spine and forearm BMD ⁵⁵	2 years of Vit D + Ca ⁺⁺ increased lumbar spine and forearm BMD ⁵⁵
	Low levels related to RA disease activity ^{25,56}	Low vit D levels increase disease activity and bone loss. ⁵⁶
	Osteoarthritis: No benefit for pain, stiffness, or function ⁵⁷	Vit D3 (800-60,000 IU) does not improve pain, stiffness, or function (2/3 studies showed improvement in knee pain on visual analogue scale) ⁵⁷
Cancer	Conflicting findings on cancer risk ^{26, 58}	<p>Cancer risk:</p> <ul style="list-style-type: none"> ◆ 1,000 IU / day vitamin D + Ca⁺⁺ 1400-1500mg/day in postmenopausal women (>55yo) had decreased rates of cancer (NNT=25/4years)_{baseline 25(OH)D=71.8 nmol/L}²⁷ ◆ 2,000IU/day vitamin D + Ca⁺⁺ 1500 mg/day postmenopausal women (>55yo) did not sig. ↓ cancer risk⁵⁸ HR 0.70 (95%CI 0.47-1.02)_{(pts were Vit D replete; mean baseline levels 32.8ng/mL (81.9 nmol/L), unknown whether Vit D would ↓ cancer risk if given to deficient pts)}
	Reduces cancer mortality ⁵⁹	<p>Cancer mortality:⁵⁹</p> <ul style="list-style-type: none"> ◆ 400-1100 IU vitamin D/day (+/- Ca⁺⁺) for 2-7 years sig. ↓ cancer mortality (RR 0.88) 95%CI 0.78-0.98 <p>Risk likely related to 25(OH)D levels: In this meta-analysis, baseline 25(OH)D was 38-74.4 nmol/L; NHANES III cohort did <u>not</u> find cancer mortality benefit with higher 25(OH)D levels²⁷</p>
	Does not reduce colon cancer risk ^{28, 60-62}	◆ Prevention RCT: Vit D 1000 IU/day + Ca ⁺⁺ 1200mg/day for 3-5 years did not sig. ↓ colorectal cancer risk, ⁶⁰ but genotype affects risk (AA genotype ↓ risk 64% ; 1 or 2 G alleles ↑ risk 41% ⁶¹)
	Colon cancer mortality inversely related to levels	◆ Mortality: inverse to 25(OH) D levels (observational studies) ⁶²
	Reduces breast cancer mortality ^{29, 30, 31,62,63}	◆ Observational studies: 25(OH)D levels correlated with lower progression/mortality ^{esp. in pre-menopausal women} ^{62,63}

Category	Claims	Evidence
		<ul style="list-style-type: none"> ♦ Meta-analysis of observational studies: Higher 25(OH)D correlated with lower case-fatality rate (highest vs. lowest quantile pooled HR 0.56, 95%CI 0.4-0.7).⁶⁴ ♦ RCT suggests safety with 10,000 IU vitamin D3 dose daily x 4 months³² <p>Consider Vit D dose <u>(benefits are dose-dependent)</u>, Ca⁺⁺ intake <u>(harms are often related to Ca⁺⁺ component)</u>!</p>
	May reduce prostate cancer progression ^{33,62}	<ul style="list-style-type: none"> ♦ Low 25(OH)D levels related to aggressive cancer (<30ng/mL associated with adverse pathology; OR 2.64_{95%CI 1.25-5.59}).⁶⁵ ♦ Inconsistent data for progression and mortality; open-label trial suggests 4,000 IU/day may ↓ progression⁶²
CV	Does not reduce cardiovascular risk ^{22,66}	♦ RCT: 200,000 IU once, then 100,000 IU monthly for 3.3 years did not reduce CV disease risk (both groups were vitamin D replete* and only half were at high CV risk; unknown if deficient or higher CV risk patients might benefit;) ⁶⁶
	Does not reduce blood pressure	♦ 100,000 IU q3 months x 1yr did not improve blood pressure ^{VITDISH}
Diabetes Mellitus (DM)	May reduce T1DM risk ²²	♦ Type 1 DM prevention: some benefit suggested in large cohort trial
	Does not reduce T2DM risk ^{68,69}	♦ Type 2 DM prevention: No benefit on insulin sensitivity, glucose control, or cardiometabolic risk ^{68,69}
	Low levels associated with CV morbidity/mortality (T2DM)	♦ Low 25(OH)D associated with higher risk of CV morbidity/mortality in T2DM ⁷³
	No benefit for non-alcoholic fatty liver disease (T2DM) ⁶⁷	♦ No benefit on non-alcoholic fatty liver disease in T2DM ⁶⁷
Renal	Kidney disease: reduces PTH, controls mineral and bone disorders ^{stage 3-5CKD 22,70,71}	<p>Chronic kidney disease:</p> <ul style="list-style-type: none"> ♦ Effective for decreasing parathyroid hormone (PTH) in patients with chronic kidney disease (but can increase calcium and phosphate) ♦ Vitamin D3 raises 25 (OH)D levels more than D2 in non-dialysis dependent CKD patients (but levels ↓ rapidly after Tx stopped); D2 and D3 equally effective in lowering PTH.⁷⁰ ♦ D2 and calcitriol equally effective to control mineral & bone disorders in stage 3-5 CKD.⁷¹ <p>Toxicity (data from Women's Health Initiative (WHI):³⁴ nephrolithiasis: Vit D3 400 IU/day + Ca⁺⁺ (~2,100mg/day total intake on average) HR=1.17 95% CI 1.02-1.34 WHI - ~ 7yr</p>
	May prevent UTI ⁹⁹	UTI: Vit D (20,000 IU/wk x 5 years) ↓ UTI risk (7% Vit D vs. 13% placebo, p<0.02) ⁹⁹
Mortality	Inverse relationship between levels and all-cause mortality ³⁵	<ul style="list-style-type: none"> ♦ Meta-analysis (N=26, 916) : 25(OH)D levels inversely related to mortality (overall & CV mortality but not cancer mortality); effects reached a threshold at 20ng/mL (50 nmol/L) for overall mortality and 30ng/mL (75nmol/L) for CV mortality (no further benefits beyond these thresholds; may explain why trials in replete* patients did not find benefits).⁷² ♦ Another meta-analysis found the same inverse relationship, but with a threshold of 30ng/mL (75 nmol/L) for all-cause mortality.⁹⁴
	Does not reduce ICU mortality or length of stay	♦ VITdAL-ICU: among critically ill pts with vit D deficiency giving 540,000 IU x1 then 90,000 IU monthly x 5 months did not reduce hospital length of stay, hospital mortality or 6 month mortality. ³⁴
Nervous System	Inverse relationship between vitamin D intake and Alzheimer's risk ⁷⁴⁻⁷⁶	♦ Alzheimer's dementia: Proposed benefit but data lacking (inverse relationship between levels/intake and risk) ⁷⁴⁻⁷⁶
	May slow Parkinson's disease progression ⁷⁷	♦ Parkinson's: RCT showing potential benefit (1,200 IU/day may slow progression) ⁷⁷

Category	Claims	Evidence
	Not effective for treating depression ⁷⁸⁻⁷⁹	♦ Depression treatment: 2 meta-analyses showed no benefit. ^{78,79}
	May reduce MS relapse rate ⁸⁰⁻⁸³	♦ MS: association between low neonatal and childhood Vit D and MS ^{80,81} , placebo-controlled trial found no changes in inflammatory markers ⁸² , but prospective cohort study found ↓ in relapse rate ⁸³ (in pts on natalizumab)
	Does not prevent ALS or slow progression ⁸⁴⁻⁸⁶	♦ ALS: Prospective cohort study found no protective effects ⁸⁴ , non-randomized comparative study found no change in prognosis (100,000IU/wk x 4 wks), ⁸⁵ and vitamin D levels do not predict survival. ⁸⁶
	Small decrease in non-specific pain ^{35,87-90}	♦ Chronic pain ³⁶ ; small ↓ in non-specific pain 6 wks post 150,000 IU PO ^{x1or2} ♦ Low vit D levels found in fibromyalgia, ⁸⁷ carpal tunnel, ⁸⁸ and chronic widespread pain, ⁸⁹ but not low back pain. ⁹⁰
Pulmonary	Reduces asthma attacks and hospitalization ^{91,96}	♦ Asthma: Cochrane review - Low Vit D levels linked to asthma severity, attacks; vitamin D ↓ avg. attacks/yr (from 0.48 to 0.22, RR 0.63, 95% CI 0.45-0.88), risk of attending hospital due to attack (from 6% to 3%, OR 0.39 95% CI 0.19-0.78). No effect on lung function or day to day symptoms. Data mostly in mild-mod asthma. ⁹¹ Vit D did not influence time to exacerbation or infections upper respiratory in asthmatics. There was no sig ↓ wheeze/asthma in kids when prenatal supplement given. ^{VDAART,Chawes'16} Low Vit D levels were not found to increase the risk of atopic disease (e.g., asthma, atopic dermatitis). ⁹⁶
	COPD: reduces mod-severe exacerbation risk (only if vit D deficient) ^{VIDiCo}	♦ COPD: Correcting Vit D deficiency (120,000 IU q2mo x 6) ↓ mod-severe exacerbation risk (HR 0.57, 95% CI 0.35-0.92, p=0.021) ONLY in Vit D deficient pts (<50nmol/L) but did not affect time to 1 st mod-severe exacerbation or time to 1 st URTI ⁹² (VIDiCo)
	Small decrease in URTI risk (mainly in vit D deficient and LTC residents)	♦ URTI: Vit D (300-2,000 IU daily or boluses of 100,000 IU monthly) ↓ acute URTI risk (OR 0.88, 95% CI 0.81-0.96) but ARR only 2% (most benefit in very deficient pts and those not receiving boluses) and definitions of URTI varied between studies (included many different conditions) ⁹³ ; reduced acute URTI in older LTC residents but more falls ^{Ginde'16}
	Reduces influenza A risk (and risk of flu-related asthma attacks) ^{in children} ⁹⁵	♦ Influenza: Vit D ↓ influenza A risk _{in schoolchildren} (RR 0.58, 95% CI 0.34-0.99, p=0.04); ↓ risk of flu-related asthma attacks (RR 0.17, 95% CI 0.04-0.73, p=0.006) ⁹⁵
	Does not help with sputum culture conversion in tuberculosis ⁹⁷	♦ TB: Vit D deficiency increases TB risk (OR 2.57, 95% CI 1.74-3.80) ⁹⁷ ; Vit D did not have any significant benefits on sputum culture conversion in active tuberculosis ⁹⁸
Skin ^{37,38}	Relieves symptoms of plaque psoriasis (topical vit D) ³⁹	♦ Psoriasis: topical vitamin D application may be useful in psoriasis but has more adverse effects when compared to corticosteroids; (ie eczema, psoriasis)
	Improves winter atopic dermatitis ^{in children} ¹⁰³	♦ Atopic dermatitis: improved winter related atopic dermatitis in children ¹⁰³
	May reduce inflammatory acne lesions ¹⁰⁰	♦ Acne: Low Vit D levels correlate with acne incidence/severity; 1,000 IU daily x 2 mo ↓ inflammatory lesions 34.6% (p<0.05). ¹⁰⁰
	Low levels may be linked to skin aging (conflicting findings) ^{101,102}	♦ Skin aging: Conflicting findings (some studies suggest a link, others do not; ethnic group may play a role) ^{101,102}

AECOPD=acute exacerbation of COPD, COPD=chronic obstructive pulmonary disease, MS=multiple sclerosis, OA=osteoarthritis, OP=osteoporosis, RA=rheumatoid arthritis, RCT=randomized controlled trial, URTI=upper respiratory tract infection

Green = consistent evidence from high quality meta-analysis or RCTs; Yellow = evidence from RCTs or lower-quality meta-analyses; Orange = evidence from observational studies, or RCT evidence with limitations or inconsistency; Pink = lack data

*Vitamin D replete = 25(OH)D levels in the 50-125 nmol/L range.

Vitamin D: What we know, what's coming next

What do we know (bottom line)?

1. Although it is suggested that there may be multiple benefits for vitamin D, the evidence for vitamin D (when used with calcium) is strongest in preventing fractures (NNT 200).
2. Cut-off points for 25(OH)D have not been well established.
3. There may be an association between low 25(OH)D and mortality, but it is unknown whether treatment will be of benefit.

What's new since the last update (Jan 2013)?

- Concept of a threshold for the association between lower 25(OH)D levels and mortality (50-75 nmol/L)^{72,94}
- New Osteoporosis Canada guidelines on preventing fracture in long-term care⁴⁶
- New evidence (see Table 2 and Figure 1)

What are the headlines saying?

The headline	The facts
There is a vitamin D deficiency “pandemic”, and most of us aren’t getting enough. Nearly everyone needs a supplement.	This “hype” stems from misinterpretation of the Institute of Medicine (IOM) vitamin D recommended 25(OH)D levels of 50 nmol/L (20 ng/mL) as a “cut point” for good bone health. But this is actually the upper end of the spectrum of human need; 97.5% of people need this amount <i>or less</i> , and 50% need 40 nmol/L (16 ng/mL) or less. This means that many people whose requirement is being met are being misclassified as “deficient”. Guidelines vary on who needs a supplement (generally those at high risk of deficiency or fracture; see Dosage Guidelines above). ¹⁰⁶
On one hand... Vitamin D is a “cure-all” that can prevent and treat a wide variety of diseases.	Correlation is not causation. Many observational studies have found relationships between low 25(OH)D levels and various diseases. But for many of these conditions, vitamin D supplementation does not result in a significant improvement. ¹⁰⁹
And on the other hand... Vitamin D does not live up to the “hype” – it’s not as effective as we hoped.	Some news stories tout vitamin D as a cure-all, while others say it’s useless and possibly harmful. The truth is somewhere in between. There is a lot of low-quality evidence linking lower levels of vitamin D to various conditions, but not much convincing evidence for supplementation except for a few key areas (see Table 2 and Figure 1). Supplementation trials may have disappointing results because vitamin D benefits are greatest in those with the lowest vitamin D levels, but many studies used patients who were vitamin D replete. Vitamin D may exhibit a “threshold effect” (only patients with levels below a certain threshold will benefit from supplementation) rather than a linear “dose response” relationship. ¹¹⁰ New studies are underway to help clarify the role of vitamin D supplementation (see below). ^{108,109,110}

What's still unclear?

1. What is the appropriate 25(OH)D level definition for vitamin D deficiency?¹⁰⁶
2. Do low 25(OH)D levels increase the risk of death?
3. What is the best 25(OH)D level range for optimal health, and is it the same for all populations and disease states?^{104,110}
4. Do dietary recommendations for vitamin D need to be updated?
5. Do vitamin D dosage guidelines need to be updated (guidelines have not been recently updated and recommendations differ)?^{105,110}
6. How safe are large doses of vitamin D, and what is the maximum daily (or weekly, monthly or yearly) dose?
7. What is the optimal dosing regimen: would daily or weekly supplementation be more effective than monthly (which can cause fluctuations in levels) for reducing cardiovascular risk? What other conditions are sensitive to 25(OH)D level fluctuations?¹⁰⁷
8. Does vitamin D supplementation reduce all-cause mortality, cancer or cardiovascular risk in people who are vitamin D deficient (most studies were in replete patients)?^{72,94}
9. What are the indications for vitamin D levels?

What upcoming studies will help us answer these questions?

Study	Expected publication date	Summary
D-HEALTH 5-year RCT	2019/early 2020's (5-year study that launched in Jan 2014)	Population: N=25,000 Australian adults aged 60-84 (no Hx of sarcoidosis, hyperparathyroidism, hypercalcemia, or kidney stones) Intervention: Vit D 60,000 IU monthly x 5 years Control: Placebo Outcomes: All-cause mortality (primary), total cancer incidence (secondary), colorectal cancer incidence (secondary) Type of question: Prevention trial Type of trial: Randomized https://dhealth.gimrberghofer.edu.au/
VITAL RCT	Enrollment will complete at end of 2017; Publication likely in 2018	Population: N=25,874 adults (Women 55 and over, men 50 and over, no Hx of cancer, heart attack or stroke) in Boston MA Intervention: Vit D 2,000 IU daily and/or omega-3 fatty acids 1 gram daily (Vit D alone, omega-3 alone, or both)

		Control: Placebo Outcomes: Risk of cancer, heart disease and stroke Type of question: Prevention trial Type of trial: Randomized http://www.vitalstudy.org/
PRECOVID 1-year RCT	Completion 2017; publication est. 2018	Population: N=240 COPD patients (40 and over with Vit D deficiency; 25(OH)D < 50 nmol/L) Intervention: Vit D 16,800 IU weekly x 1 year Control: Placebo Outcomes: Exacerbation rate (primary); physical performance, QOL Type of question: Treatment trial Type of trial: Randomized https://bmcpulmed.biomedcentral.com/articles/10.1186/s12890-015-0101-4

Acknowledgements: We would like to thank those who contributed to the development and review of various components of this newsletter & accompanying chart. Dr. W. Olszynski (Rheumatology, Saskatoon), Dr. Susan Whiting (C. of Pharmacy & Nutrition, U of S), Dr. R. Gjevrev (Rheumatology, Saskatoon), Dr. T. Laubscher (Family Medicine, U of S, Saskatoon), Dr. J. Richardson (SHR Pharmacy), Dr. Y. Shevchuk (C. of Pharmacy & Nutrition, U of S), Dr. J. Taylor (C. of Pharmacy & Nutrition, U of S), K. Jensen (SDIS-C. of Pharmacy & Nutrition, U of S), M. Jin (Ontario), I. Fleming (Dalhousie Academic Detailing Service, Nova Scotia), & the RxFiles Advisory Committee. Prepared by: Shannon Stone BSP; Loren Regier BSP BA, Brent Jensen BSP.

DISCLAIMER: The content of this newsletter represents the research, experience and opinions of the authors and not those of the Board or Administration of Saskatchewan Health Region (SHR). Neither the authors nor Saskatchewan Health Region nor any other party who has been involved in the preparation or publication of this work warrants or represents that the information contained herein is accurate or complete, and they are not responsible for any errors or omissions or for the result obtained from the use of such information. Any use of the newsletter will imply acknowledgment of this disclaimer and release any responsibility of SHR, its employees, servants or agents. Readers are encouraged to confirm the information contained herein with other sources. Additional information and references online at www.RxFiles.ca

Copyright 2010, 2016, 2017 – RxFiles, Saskatoon Health Region (SHR) www.RxFiles.ca

- 1 Vitamin D dosing. Pharmacist's letter/Prescriber's letter 2009;25(5):250508.
- 2 Vitamin D dosing: and update, Pharmacist's Letter/Prescriber's Letter 2010;26(7):26077
- 3 Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-81
- 4 Dawson-Hughes B, Mithal A, Bonjour JP, Boonen S, Burckhardt P, Fuleihan GE, Josse RG, Lips P, Morales-Torres J, Yoshimura N. IOF position statement: vitamin D recommendations for older adults. Osteoporos Int. 2010 Jul;21(7):1151-4.
- 5 Langlois K, Greene-Finestone L, Little J, Hidiroglou N, Whiting S. Vitamin D status of Canadians as measured in the 2007 to 2009 Canadian Health Measures Survey. Health Rep. 2010 Mar;21(1):47-55.
- 6 Hanley David A, Cranney Ann, Jones, Glenville, et al. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada – summary. CMAJ 2010 0: cmaj.091062
- 7 Canadian Cancer Society http://www.cancer.ca/Canada-wide/Prevention/Vitamin%20D.aspx?sc_lang=en (Accessed 17 September 2010)
- 8 Canadian pediatric society. Vitamin D supplementation: recommendations for Canadian mothers and infants. Paediatr Child Health 2007;12(7):583-9
- 9 Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr. 2001 Feb;73(2):288-94.
- 10 Aloia JF, Patel M, Dimaanano R, Li-Ng M, Talwar SA, Mikhail M, Pollack S, Yeh JK. Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. Am J Clin Nutr. 2008 Jun;87(6):1952-8.
- 11 Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet. 1998 Mar 14;351(9105):805-6.
- 12 Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-81
- 13 Sanders Kerrie M.; Stuart Amanda L.; Williamson Elizabeth J.; et al. Annual High-Dose Oral Vitamin D (500,000 IU x1yr for 3-5yrs) and Falls and Fractures in Older Women: A Randomized Controlled Trial. JAMA. 2010;303(18):1815-1822.
- 14 Smith H, Anderson F, Raphael H, et al. Effect of annual intramuscular vitamin D on fracture risk in elderly men and women—a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford). 2007 Dec;46(12):1852-7.
- 15 Avenell A, Gillespie W, Gillespie L, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and postmenopausal osteoporosis. Cochrane Database Syst Rev. 2009;2(2):CD000227.
- 16 Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet 2005;365(9471):1621-8.
- 17 Avenell A, MacLennan GS, Jenkinson DJ, et al. Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D3 and/or calcium (RECORD trial). J Clin Endocrinol Metab 2011; DOI:10.1210/jc.2011-1309.
- 18 Office of Dietary Supplements, National Institutes of Health. Dietary Supplement Facts Sheet: Vitamin D. <http://ods.od.nih.gov/factsheets/vitaminD.asp> (Accessed September 7, 2010)
- 19 Heaney RP. Vitamin D and calcium interactions: functional outcomes. Am J Clin Nutr. 2008 Aug;88(2):541S-544S.
- 20 OHTAC (Ontario Health Technology Advisory Committee) Recommendation June 2010 Clinical Utility of Vitamin D Testing http://www.health.gov.on.ca/english/providers/program/ohatc/ohatc_tech/recommend/rec_vitamin%20d_201002.pdf
- 21 Hanley David A, Cranney Ann, Jones, Glenville, et al. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada – summary. CMAJ 2010 0: cmaj.091062
- 22 Stone S. Vitamin D Trials Summary Chart. Oct 2010. RxFiles: accessed at: <http://www.rxfiles.ca/rxfiles/uploads/documents/members/VitaminD-trial-summary-chart.pdf>
- 23 Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med. 2009 Mar 23;169(6):551-61.
- 24 Avenell A, Mak JC, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev. 2014 Apr 14;CD000227. Vitamin D alone is unlikely to prevent fractures in the doses and formulations tested so far in older people. Supplements of vitamin D and calcium may prevent hip or any type of fracture. There was a small but significant increase in gastrointestinal symptoms and renal disease associated with vitamin D and calcium. This review found that there was no increased risk of death from taking calcium and vitamin D.
- 25 Fosnight SM, Zafirou WJ, Hazlett SE. Vitamin D supplementation to prevent falls in the elderly: evidence and practical considerations. Pharmacotherapy. 2008 Feb;28(2):225-34.
- 26 Bischoff-Ferrari H A, Dawson-Hughes B, Staehelin H B, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 2009;339. Panel on Prevention of Falls in Older Persons, American Geriatrics Society (AGS) and British Geriatrics Society. Summary of Updated American Geriatrics Society/British Geriatrics Society Clinical Practice Guideline for Prevention of Falls in Older Persons. Article first published online: 13 JAN 2011 DOI: 10.1111/j.1532-5415.2010.03234.x <http://onlinelibrary.wiley.com/doi/10.1111/j.1532-5415.2010.03234.x/pdf>
- 27 Merlino LA, Curtis J, Miklus TR, et al. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum 2004;50:72-7.
- 28 Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007 Jun;85(6):1586-91.
- 29 Freedman DM, Looker AC, Abnet CC, Linet MS, Graubard BI. Serum Vitamin D and Cancer Mortality in the NHANES III Study (1988-2006). Cancer Res. 2010 Sep 16.
- 30 Gorham ED, Garland CF, Garland WB, Mohr SB, Lipkin M, Newmark HL, Giovannucci E, Wei M, Holick MF. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta-analysis. Am J Prev Med. 2007 Mar;32(3):210-6.
- 31 Baron JA, Barry EL, Mott LA, et al. A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. N Engl J Med. 2015 Oct 15;373(16):1519-30.
- 32 Chlebowski RT, Johnson KC, Kooperberg C, et al. Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. 2008 Nov 19;100(22):1581-91.
- 33 Freedman DM, Chang SC, Falk RT, et al. Serum levels of vitamin D metabolites and breast cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev 2008;17(4):889-894.
- 34 Lin J, Manson JE, Lee IM, Cook NR, Buring JE, Zhang SM. Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med. 2007 May 28;167(10):1050-9.
- 35 Amir E, Simmons CE, Freedman OC, Dranitsaris G, Cole DE, Vieth R, Ooi WS, Clemons M. A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases. Cancer. 2010;116(2):284-91.
- 36 Barnett CM, Nielson CM, Shannon J, Chan JM, Shikany JM, Bauer DC, Hoffman AR, Barrett-Connor E, Orwoll E, Beer TM. Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control. 2010 Aug;21(8):1297-303. Epub 2010 Apr 10
- 37 Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al; Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006 Feb 16;354(7):669-83.
- 38 Jang T, Pearson C. Vitamin D blood levels of Canadians. Statistics Canada 2015. <http://www.statcan.ca/pub/82-624-x/20133001/article/11727-eng.htm>
- 39 National Institutes of Health. Vitamin D: Fact sheet for health professionals. Updated Feb. 11, 2016. <https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/>
- 40 Health Canada. Vitamin D and calcium: Updated dietary reference intakes. <http://www.hc-sc.gc.ca/fn-an/nutrition/vitamin/vita-d-eng.php>. Updated Mar. 22, 2012.
- 41 Scientific Advisory Committee on Nutrition (SACN). Vitamin D and health (2016). <https://www.gov.uk/government/groups/scientific-advisory-committee-on-nutrition>.
- 42 Osteoporosis Canada. Recommendations for preventing fracture in long-term care (2015). <http://www.cmaj.ca/content/early/2015/09/14/cmaj.141331>.
- 43 Kearns MD, Alvarez JA, Tangpricha V. Large, single-dose, oral vitamin D supplementation in adult populations: a systematic review. Endocr Pract. 2014 April ; 20(4): 341–351. doi:10.4158/EP13265.RA. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128480/pdf/nihms605790.pdf>.
- 44 Murad MH, Elamin KB, Abu Elnour NO, Elamin MB, Alkhatib AA, Fatourechi MM, et al. The effect of vitamin D on falls: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011 Jul 27;96(10):2997-3006.
- 45 Canadian Agency for Drugs and Technologies in Health (CADTH). Vitamin D Supplementation for the Prevention of Falls and Fractures in Residents in Long-Term Care Facilities: A Review of the Clinical Effectiveness, Cost-Effectiveness, or Guidelines. <https://www.cadth.ca/sites/default/files/pdf/htis/apr-2016/RC0770%20Vit%20D%20in%20long-term%20care%20Final.pdf>.
- 46 Cameron ID, Gillespie LD, Robertson MC, Murray GR, Hill KD, Cumming RG, Kerse N. Interventions for preventing falls in older people in care facilities and hospitals. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD005465. DOI: 10.1002/14651858.CD005465.pub3.
- 47 Guo JL, Tsai YY, Liao JY, et al. Interventions to reduce the number of falls among older adults with/without cognitive impairment: an exploratory meta-analysis. Int J Geriatr Psychiatry 2014; 29: 661–669.
- 48 Kalyani RR, Stein B, Valiylil R, et al. Vitamin D Treatment for the Prevention of Falls in Older Adults: Systematic Review and Meta-Analysis. J Am Geriatr Soc 58:1299–1310, 2010.
- 49 Stubbs B, Denking MD, Breika A, et al. What works to prevent falls in older adults dwelling in long term care facilities and hospitals? An umbrella review of meta-analyses of randomised controlled trials. Maturitas 81 (2015) 335–342.
- 50 Reid IR, Bolland MJ, Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet 2014;383 (9912):146-155.
- 51 Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database of Systematic Reviews 1998; <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000952/full>.
- 52 Hong Q, Xu J, Xu S, et al. Associations between serum 25-hydroxyvitamin D and disease activity, inflammatory cytokines and bone loss in patients with rheumatoid arthritis. Rheumatology 2014;53:1994-2001. doi:10.1093/rheumatology/keu173.
- 53 Hussain S, Singh A, Akhtar M, Najmi AK. Vitamin D supplementation for the management of knee osteoarthritis: a systematic review of randomized controlled trials. Rheumatol Int. 2017 Apr 18. doi: 10.1007/s00296-017-3719-0.
- 54 Lappe J, Watson P, Travers-Gustafson D. Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial. JAMA. 2017;317(12):1234-1243. doi:10.1001/jama.2017.2115.
- 55 Keum N, Giovannucci E. Vitamin D supplements and cancer incidence and mortality: a meta-analysis. British Journal of Cancer (2014) 111, 976–980 | doi: 10.1038/bjc.2014.294.
- 56 Baron JA, Barry EL, Mott LA, et al. A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. N Engl J Med 2015; 373:1519-1530.
- 57 Barry EL, Peacock JK, Rees JQ. Vitamin D Receptor Genotype, Vitamin D₃ Supplementation, and Risk of Colorectal Adenomas: A Randomized Clinical Trial. JAMA Oncol. 2017;3(5):628-635. Doi:10.1001/jamaoncol.2016.5917.
- 58 Jacobs ET, Kohler LN, Kunihiro AG, Jurutka PW. Vitamin D and colorectal, breast, and prostate cancers: a review of the epidemiological evidence. J Cancer. 2016; 7(3): 232–240.
- 59 Yao S, Kwan ML, Ergas IJ. Association of serum level of vitamin D at diagnosis with breast cancer survival. JAMA Oncol. 2017;3(3):351-357. doi:10.1001/jamaoncol.2016.4188.
- 60 Mohr SB, Gorham Ed, Kim J, et al. Meta-analysis of vitamin D sufficiency for improving survival of patients with breast cancer. Anticancer Research 2014;34:1163-1166.
- 61 Nyame YA, Murphy AB, Bowen DK, et al. Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy. J Clin Oncol. 2016 Apr 20; 34(12): 1345-1349.
- 62 Scragg R, Stewart AW, Waayer D, et al. Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the vitamin D assessment study. JAMA Cardiology 2017; Published online April 5, 2017. doi:10.1001/jamacardio.2017.0175.
- 63 Barchetta I, Del Ben M, Angelico F, et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Med. 2016 Jun 29;14:92. doi: 10.1186/s12916-016-0638-y.
- 64 Wagner H, Alvarsson M, Mannheimer B, et al. No Effect of High-Dose Vitamin D Treatment on β-Cell Function, Insulin Sensitivity, or Glucose Homeostasis in Subjects With Abnormal Glucose Tolerance: A Randomized Clinical Trial. Diabetes Care. 2016 Mar;39(3):345-52. doi: 10.2337/15-1057. Epub 2016 Jan 19.

69. Ferozhi NG, Menon RK, Sharp SJ, et al. Effects of vitamin D2 or D3 supplementation on glycaemic control and cardiometabolic risk among people at risk of type 2 diabetes: results of a randomized double-blind placebo-controlled trial. *Diabetes, Obesity and Metabolism* 18: 392–400, 2016.
70. Wetmore JB, Kimber C, Mahnkens JD, Stubbs JR. Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial. *Br J Nutr*. 2016 Dec;116(12):2074–2081. doi: 10.1017/S000711451600427X. Epub 2017 Jan 9.
71. Zhang D, Li H, Wang L, Ma Y. Ergocalciferol versus calcitriol for controlling chronic kidney disease mineral bone disorder in stage 3 to 5 CKD: A randomized controlled trial. *Eur J Pharmacol*. 2016 Oct 15;789:127–33. doi: 10.1016/j.ejphar.2016.07.019. Epub 2016 Jul 9.
72. Gaksch M, Jorde R, Grimnes G, et al. Vitamin D and mortality: Individual participant data meta-analysis of standardized 25-hydroxyvitamin D in 26916 individuals from a European consortium. *PLoS One* 12(2): e0170791. doi:10.1371/journal.pone.0170791.
73. Samefoms M, Scragg R, Lanne T, et al. Association between serum 25(OH)D3 and cardiovascular morbidity and mortality in people with Type 2 diabetes: a community-based cohort study. *Diabet Med* 2016; DOI: 10.1111/dme.13290.
74. Littlejohns TJ, Henley WE, Anweiler C, et al. Vitamin D and the risk of dementia and Alzheimer disease. *Neurology* 2014; 83:920–928.
75. Anweiler C, Rolland Y, Schott AM, et al. Higher vitamin D intake is associated with lower risk of Alzheimer's disease: a 7-year follow-up.
76. Fear C, Helmer C, Merle B, et al. Associations of lower vitamin D concentrations with cognitive decline and long-term risk of dementia and Alzheimer's disease in older adults. *Alzheimers Dement* 2017 May 9 (pub ahead of print) pii: S1552-5260(17)30138-3.
77. Rimmelzwaan LM, van Schoor NM, Lips P, et al. Systematic review of the relationship between vitamin D and Parkinson's disease. *Journal of Parkinson's Disease* 2016;6:29-37.
78. Li G, Mbaugbaw L, Samaan Z, et al. Efficacy of vitamin D supplementation on depression in adults: a systematic review.
79. Gowda U, Mutwop MR, Smith BJ, et al. Vitamin D supplementation to reduce depression in adults: meta-analysis of randomized controlled trials. *Nutrition* 2015; 31(3):421-429.
80. Gianfrancesco MA, Strieth P, Rhead B, et al. Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. *Neurology* 2017;88(17):1623-1629.
81. Nielsen NM, Munger KL, Koch-Henriksen N, et al. Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study. *Neurology* 2017;88(1):44-51.
82. Rosio E, Steffensen LH, Jorgensen L, et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. *J Neurol* 2015;262(12):2713-2721.
83. Laursen JH, Sondergaard HB, Sorensen PS, et al. Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab. *Mult Scler Relat Disord* 2016;10:169-173.
84. Blasco H, Hounoum BM, Dufour-Rainfray D, et al. Vitamin D is not a protective factor in ALS. *CNS Neuroscience & Therapeutics* 2015;21:651-656.
85. Libonati L, Onesti E, Gori MC, et al. Vitamin D in amyotrophic lateral sclerosis. *Functional Neurology* 2017;32(1):35-40.
86. Yang J, Park JS, Oh KW, et al. Vitamin D levels are not predictors of survival in a clinic population of patients with ALS. *J Neurol Sci* 2016;367:83-88.
87. Karas R, Rapiti E, Matsoukas S, et al. Vitamin D in fibromyalgia: a causative or confounding biological interplay? *Nutrients* 2016;8:343. doi: 10.3390/nu8060343.
88. Tanik N, Balbaloglu O, Ucar M, et al. Does vitamin D deficiency trigger carpal tunnel syndrome? *J Back Musculoskeletal Rehabil*. 2016;29(4):835-839.
89. McCabe PS, Pye SR, McBeth J, et al. Low vitamin D and the risk of developing chronic widespread pain: results from the European male aging study. *BMC Musculoskeletal Disorders* 2016;17:32.
90. Thomeby A, Nordeman LM, Johanson EH. No association between level of vitamin D and chronic low back pain in Swedish primary care: a cross-sectional case-control study. *Scandinavian Journal of Primary Health Care*. 2016;34(2):195-203.
91. Martineau AR, Cates CJ, Urashima M, Jensen M, Griffiths AP, Nurmatov U, Sheikh A, Griffiths CJ. Vitamin D for the management of asthma. *Cochrane Database of Systematic Reviews* 2016, Issue 9. Art. No.: CD011511. DOI: 10.1002/14651858.CD011511.pub2.
92. Martineau AR, James WY, Hooper RL, et al. Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (VIDICO): a multicentre, double-blind, randomised controlled trial.
93. Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. *BMJ* 2017;356:i6583 | doi: 10.1136/bmj.i6583.
94. Garland CF, Kim JJ, Mohr SB, et al. Meta-analysis of all-cause mortality according to serum 25-hydroxyvitamin D. *Am J Public Health* 2014; 104(8):e43-e50.
95. Urashima M, Segawa T, Okazaki M, et al. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. *Am J Clin Nutr* 2010;91:1255-60.
96. Manousaki D, Patemoster L, Standl M, et al. Vitamin D levels and susceptibility to asthma, elevated immunoglobulin E levels, and atopic dermatitis: A Mendelian randomization study. *PLOS Medicine* 2017; <https://doi.org/10.1371/journal.pmed.1002294>.
97. Huang SJ, Wang XH, Liu ZD, et al. Vitamin D deficiency and the risk of tuberculosis: a meta-analysis. *Drug Design, Development and Therapy* 2017;11:91-102.
98. Grobler L, Nagpal S, Sudarsanam TD, Sinclair D. Nutritional supplements for people being treated for active tuberculosis. *Cochrane Database of Systematic Reviews* 2016, Issue 6. Art. No.: CD006086. DOI: 10.1002/14651858.CD006086.pub4.
99. Jorde R, Sollid ST, Svartberg J, et al. Prevention of urinary tract infections with vitamin D supplementation 20,000 IU per week for five years. Results from an RCT including 511 subjects. *Infect Dis (Lond)*. 2016 NovDec;48(11):8238. doi: 10.1080/23744235.2016.1201853.
100. Lim SK, Ha JM, Lee YH, et al. Comparison of Vitamin D Levels in Patients with and without Acne: A Case-Control Study Combined with a Randomized Controlled Trial. *PLOS ONE* 2016; DOI:10.1371/journal.pone.0161162.
101. Dawoud NM, Bakry OA, Shoeb MA, Ismael HN. Serum vitamin D and skin aging: Is there a link? *Skin Pharmacol Physiol* 2016;29:76–82. DOI: 10.1159/000443839.
102. Chang AL, Fu T, Amir O, Tang JY. Association of facial skin aging and vitamin D levels in middle-aged white women. *Cancer Causes Control*. 2010 December ; 21(12): 2315–2316. doi:10.1007/s10552-010-9646-y.
103. Camargo CA Jr, Ganmaa D, Sidbury R, et al. Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children. *J Allergy Clin Immunol*. 2014 Oct;134(4):831-835.e1.
104. Tello M. Vitamin D: What's the 'right' level? <http://www.health.harvard.edu/blog/vitamin-d-whats-right-level-2016121910893>.
105. Spector T. Should healthy people take a vitamin D supplement in winter months? *BMJ* 2016;355:i183 doi: 10.1136/bmj.i183.
106. Manson JE, Brannon PM, Rosen CJ, Taylor CL. Vitamin D deficiency – Is there really a pandemic? *N Engl J Med* 2016; 375:19:1817-1820.
107. Science Media Centre. Expert reaction to a study investigating the effect of monthly vitamin D supplementation on cardiovascular disease. <http://www.sciencemediacentre.org/expert-reaction-to-a-study-investigating-the-effect-of-monthly-vitamin-d-supplementation-on-cardiovascular-disease29595-2/>.
108. Bolland MJ, Avenell A. Do vitamin D supplements help prevent respiratory tract infections? *BMJ* 2017; 356:j456 doi: 10.1136/bmj.j456.
109. Allan GM, Cranston L, Lindblad A, et al. Vitamin D: A narrative review examining the evidence for ten beliefs. *J Gen Intern Med* 2016; 31(7):780–91. DOI: 10.1007/s11606-016-3645-y.
110. Stokes SC, Lammert F. Vitamin D supplementation: Less controversy, more guidance needed. *F1000Research* 2016, 5(F1000 Faculty Rev):2017 (doi: 10.12688/f1000research.8863.1).
111. US Preventive Services Task Force (USPSTF). Draft recommendation statement. *Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Adults: Preventive Medication*. <https://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement/vitamin-d-calcium-or-combined-supplementation-for-the-primary-prevention-of-fractures-in-adults-preventive-medication>.
112. Choosing Wisely Canada. Vitamin D tests: When you need them and when you don't. <https://choosingwiselycanada.org/vitamin-d-tests/>.
113. Alberta College of Family Physicians. Vitamin D levels: Vitamin D or Vitamin Don't? https://www.acfp.ca/wp-content/uploads/tools-for-practice/1397843445_20140203_102028.pdf.

Additional References

- Abrams SA; the Committee on Nutrition. Calcium and Vitamin D Requirements of Enteral Fed Preterm Infants. *Pediatrics*. 2013 Apr 29.
- ACOG: Committee Opinion No. 495: **Vitamin D: Screening and Supplementation During Pregnancy**. July 2011 - Volume 118 - Issue 1 - ppg 197-198. doi: 10.1097/AOG.0b013e318227f06b
- Afzal S, Brøndum-Jacobsen P, Bojesen SE, Nordestgaard BG. **Genetically low vitamin D concentrations and increased mortality: mendelian randomization analysis in three large cohorts**. *BMJ*. 2014 Nov 18;349:g6330.
- Aghajafari F, Nagulesapillai T, Ronskley PE, Tough SC, O'Beirne M, Rabi DM. Association between maternal serum 25-hydroxyvitamin D level and **pregnancy and neonatal outcomes**: systematic review and meta-analysis of observational studies. *BMJ* 2013;346:f1169.
- Aluisio AR, Maroof Z, Chandramohan D, et al. Vitamin D3 Supplementation and Childhood **Diarrhea**: A Randomized Controlled Trial. *Pediatrics*. 2013 Sep 9. (100,000IU quarterly x 6, NS)
- Amaral AF, Méndez-Perutz M, Muñoz A, et al. Plasma 25-Hydroxyvitamin D3 and **Bladder Cancer Risk** According to Tumor Stage and FGFR3 Status: A Mechanism-Based Epidemiological Study. *J Natl Cancer Inst*. 2012 Oct 29.
- Ananthakrishnan AN, Khalili H, Higuchi LM, et al. Higher predicted vitamin D status is associated with reduced risk of **Crohn's** disease. *Gastroenterology*. 2012 Mar;142(3):482-9.
- American Geriatrics Society** Workgroup on Vitamin D Supplementation for Older Adults. Recommendations Abstracted from the American Geriatrics Society Consensus Statement on Vitamin D for Prevention of Falls and Their Consequences. *J Am Geriatr Soc*. 2013 Dec 18.
- Amrein K, Schmedl C, Holl A, et al. Effect of High-Dose Vitamin D3 on Hospital Length of Stay in **Critically Ill** Patients With Vitamin D Deficiency: The **VITdAL-ICU** Randomized Clinical Trial. *JAMA*. 2014 Oct 15;312(15):1520-1530.
- Anglin RE, Samaan Z, Walter SD, McDonald SD. Vitamin D deficiency and **depression** in adults: systematic review and meta-analysis. *Br J Psychiatry*. 2013 Feb;202:100-7.
- Aucoin M, Weaver R, Thomas R, et al. **Vitamin D status of refugees** arriving in Canada: Findings from the Calgary Refugee Health Program. *Can Fam Physician*. 2013 Apr;59(4):e188-94.
- Arora P, Song Y, Dusek J, et al. Vitamin D Therapy in Individuals With **Prehypertension or Hypertension**: The **DAYLIGHT** Trial. *Circulation*. 2015 Jan 20;131(3):254-62.
- Autier P, Boniol M, Pizot C, et al. **Vitamin D status and ill health**: a systematic review. *Lancet Diabetes Endocrinol*. 2014 Jan;2(1):76-89.
- Avenell A, Cook JA, MacLennan GS, McPherson GC; **RECORD** trial group. Vitamin D supplementation and type 2 **diabetes**. *Age Ageing*. 2009;38(5):606-609.
- Avenell A, MacLennan GS, Jenkinson DJ, et al. Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D3 and/or calcium (**RECORD** trial). *J Clin Endocrinol Metab* 2011; DOI:10.1210/jc.2011-1309.
- Avenell A, Mak JC, O'Connell D. Vitamin D and vitamin D analogues for preventing **fractures** in post-menopausal women and older men. *Cochrane Database Syst Rev*. 2014 Apr 14;CD000227. Vitamin D alone is unlikely to prevent fractures in the doses and formulations tested so far in older people. Supplements of vitamin D and calcium may prevent hip or any type of fracture. There was a small but significant increase in gastrointestinal symptoms and renal disease associated with vitamin D and calcium. This review found that there was no increased risk of death from taking calcium and vitamin D.
- Baron JA, Barry EL, Mott LA, et al. A Trial of Calcium and Vitamin D for the Prevention of **Colorectal Adenomas**. *N Engl J Med*. 2015 Oct 15;373(16):1519-30.
- Basatemur E, Horsfall L, Marston L, et al. Trends in the Diagnosis of Vitamin D Deficiency. *Pediatrics*. 2017 Feb 3.
- Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Krstic G, Watterslev J, Gluud C. Vitamin D supplementation for **prevention of cancer** in adults. *Cochrane Database of Systematic Reviews* 2014, Issue 6. Art. No.: CD007469. DOI: 10.1002/14651858.CD007469.pub2. There is currently no firm evidence that vitamin D supplementation decreases or increases cancer occurrence in predominantly elderly community-dwelling women. Vitamin D supplementation decreased cancer mortality and vitamin D supplementation decreased all-cause mortality, but these estimates are at risk of type I errors due to the fact that too few participants were examined, and to risks of attrition bias originating from substantial dropout of participants. Combined vitamin D and calcium supplements increased nephrolithiasis, whereas it remains unclear from the included trials whether vitamin D, calcium, or both were responsible for this effect.
- Barake M, Daher RT, Salti I, Cortas et al. **25-hydroxyvitamin D assay variations** and impact on clinical decision making. *J Clin Endocrinol Metab*. 2012 Mar;97(3):835-43.
- BC Guideline**: Medical Services Commission. Vitamin D testing protocol. Victoria (BC): British Columbia Medical Services Commission; 2010 Oct 1. 6 p. [19 references] <http://www.bcguidelines.ca/pdf/vitamind.pdf>
- Bertone-Johnson ER et al. Vitamin D supplementation and **depression** in the **Women's Health Initiative** Calcium and Vitamin D Trial. *Am J Epidemiol* 2012 Jul 1; 176:1.
- Beveridge LA, Struthers AD, Khan F, et al. D-PRESSURE Collaboration. Effect of Vitamin D Supplementation on **Blood Pressure**: A Systematic Review and Meta-analysis Incorporating Individual Patient Data. *JAMA Intern Med*. 2015 Mar 16.
- Birken CS, Lobovic G, Anderson LN, et al. Association between **vitamin D and circulating lipids** in early **childhood**. *PLoS One* 2015.
- Bischoff-Ferrari HA, Willett WC, Oray EJ, et al. A pooled analysis of **vitamin D dose** requirements for fracture prevention. *N Engl J Med* 2012;367:40-9. (highest actual-intake quartile (792 to 2000 IU daily), there was a 30% reduction in hip fracture incidence)
- Bischoff-Ferrari HA, Dawson-Hughes B, Orave JE, et al. **Monthly high-dose vitamin D** treatment for the prevention of **functional decline** [online Jan 4, 2016]. *JAMA Intern Med*. doi:10.1001/jamainternmed.2015.7148.
- Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for **prevention of mortality in adults**. *Cochrane Database of Systematic Reviews* 2011, Issue 7. Art. No.: CD007470. DOI: 10.1002/14651858.CD007470.pub2. Vitamin D in the form of vitamin D3 seems to decrease mortality in predominantly elderly women who are mainly in institutions and dependent care. Vitamin D2,

alfacalcidol, and calcitriol had no statistically significant effect on mortality. Vitamin D3 combined with calcium significantly increased nephrolithiasis. Both alfacalcidol and calcitriol significantly increased hypercalcaemia.

Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for **prevention of mortality in adults**. Cochrane Database Syst Rev. 2014 Jan 10;1:CD007470. Vitamin D3 seemed to decrease mortality in elderly people living independently or in institutional care. Vitamin D2, alfacalcidol and calcitriol had no statistically significant beneficial effects on mortality. Vitamin D3 combined with calcium increased nephrolithiasis. Both alfacalcidol and calcitriol increased hypercalcaemia. Because of risks of attrition bias originating from substantial dropout of participants and of outcome reporting bias due to a number of trials not reporting on mortality, as well as a number of other weaknesses in our evidence, further placebo-controlled randomised trials seem warranted.

Binkley N et al. Evaluation of ergocalciferol or cholecalciferol dosing, 1600 IU daily or 50,000 IU monthly in older adults. *J Clin Endocrinol Metab* 2011 Apr; 96:981.

Bolland MJ, Grey A, Gamble GD, et al. The effect of **vitamin D supplementation on skeletal, vascular, or cancer outcomes**: a trial sequential meta-analysis. *Lancet Diabetes Endocrinol*. 2014 Apr;2(4):307-20.

Bosomworth, N. J. Mitigating epidemic vitamin D deficiency: The agony of evidence. *Can Fam Physician* 2011 57: 16-20.

Brehm JM, Acosta-Pérez E, Klei L, et al. Vitamin D Insufficiency and Severe **Asthma Exacerbations** in Puerto Rican Children. *Am J Respir Crit Care Med*. 2012 May 31.

Bunyavanich S, Rifas-Shiman SL, Platt-Mills TA, et al. Prenatal, perinatal, and childhood vitamin D exposure and their association with **childhood allergic rhinitis and allergic sensitization**. *J Allergy Clin Immunol*. 2016 Feb 10. pii: S0091-6749(16)00035-X.

CADTH – HTA Publication: Issue 12: Vitamin D Supplements for Elderly Patients in Residential Care: Policies and Protocols – Dec 2010
http://www.cadth.ca/index.php/en/hta/reports-publications/search/publication/2748%2B?utm_source=newsletter&utm_medium=webmail&utm_campaign=newsletter-2010-12-20

Camargo CA Jr, Gamboa D, Sidbury R, et al. Randomized trial of vitamin D supplementation for winter-related **atopic dermatitis** in children. *J Allergy Clin Immunol*. 2014 Oct;134(4):831-835.e1.

Caruso TJ, Fuzaylov G. Images in clinical medicine. Severe vitamin D deficiency—rickets. *N Engl J Med*. 2013 Aug 29;369(9):e11.

Castro M, King TS, Kunselman SJ, et al; for the National Heart, Lung, and Blood Institute's AsthmaNet. Effect of **Vitamin D3 on Asthma Treatment Failures** in Adults With Symptomatic Asthma and Lower Vitamin D Levels: The **VIDA** Randomized Clinical Trial. *JAMA*. 2014 May 18.

Chaves BL, Bonnellykke K, Stokholm J, et al. Effect of vitamin D3 supplementation during pregnancy on risk of persistent **wheeze** in the offspring. *JAMA*. doi:10.1001/jama.2015.18318

Chlebowski RT, Pettinger M, Johnson KC, et al. Calcium Plus Vitamin D Supplementation and Joint Symptoms in Postmenopausal Women in the Women's Health Initiative Randomized Trial. *J Acad Nutr Diet*. 2013 Aug 14.

Chowdhury R, Kunutsor, S, Vitezova A, Oliver-Williams C, Kieffe-de Jong J, Khan H, et al. Vitamin D and **risk of cause specific death**: systematic review and meta-analysis of prospective observational and randomised intervention studies. *BMJ* 2014;348:g1903.

Chung M, Balk E. M., Brendel M., Ip, S., Lau, J., Lee, J., Lichtenstein, A., Patel, K., Raman, G., Tatsioni, A., Terasawa, T., and Trikalinos, T. A. Vitamin D and calcium: a systematic review of health outcomes. [Internet]. Rockville, MD: Agency for Healthcare Research and Quality. 2009 [cited: 2009 Sep 1]. 342 p. Evidence report No. 183. Available from: <http://www.ahrq.gov/downloads/pub/evidence/pdf/vitadcal/vitadcal.pdf>

Chung M, Lee J, Terasawa T, et al. **Vitamin D With or Without Calcium** Supplementation for Prevention of Cancer and **Fractures**: An Updated Meta-analysis for the U.S. Preventive Services Task Force (USPSTF). *Ann Intern Med*. 2011 Dec 20;155(12):827-38.

Cooper C, Harvey NC, Bishop NJ, et al, and the MAVIDOS Study Group. **Maternal gestational vitamin D supplementation and off spring bone health (MAVIDOS)**: a multicentre, double-blind, randomised placebo-controlled trial. *Lancet Diabetes Endocrinol* 2016; online March 1.

Cranney, A., Horsley, T., O'Donnell, S., Weiler, H., Pui, L., Ooi, D., Atkinson, S., Ward, L., Moher, D., Hanley, D., Fang, M., Yazdi, F., Garrity, C., Sampson, M., Barrowman, N., Tsertsivadze, A., and Mamaladez, V. Effectiveness and safety of vitamin D in relation to bone health [Internet]. Rockville, MD: Agency for Healthcare Research and Quality. 2007 [cited: 2009 Sep 1]. 235 p. AHRQ Publication No. 07-E013. Available from: <http://www.ahrq.gov/downloads/pub/evidence/pdf/vitamind/vitamind.pdf>

Daley P, Jagannathan V, John KR, et al. Adjuvant vitamin D for treatment of active **tuberculosis** in India: a randomised, double-blind, placebo-controlled trial. *Lancet Infect Dis*. 2015 Apr 8.

Denlinger LC, King TS, Cardet JC, et al; NHLBI AsthmaNet Investigators. Vitamin D Supplementation and the **Risk of Colds in Patients with Asthma**. *Am J Respir Crit Care Med*. 2016 Mar 15;193(6):634-41.

de Boer IH, Levin G, Robinson-Cohen C, et al. Serum 25-hydroxyvitamin D concentration and risk for major clinical disease events in a community-based population of older adults: a cohort study. *Ann Intern Med*. 2012 May 1;156(9):627-34.

De-Regil LM, Palacios C, Ansary A, et al. Vitamin D supplementation for women during **pregnancy**. Cochrane Database Syst Rev. 2012 Feb 15;2:CD008873.

Dore RK. Should healthy people take **calcium and vitamin D to prevent fractures**? What the US Preventive Services Task Force and others say. *Cleve Clin J Med*. 2013 Jun;80(6):341-4.

Dudenkov DV, Yawn BP, Oberhelman SS, et al. **Changing Incidence of Serum 25-Hydroxyvitamin D Values Above 50 ng/mL**: A 10-Year Population-Based Study. *Mayo Clin Proc*. 2015 May;90(5):577-86.

Elder CJ, Bishop NJ. **Rickets**. *Lancet*. 2014 Jan 9

Feskanič D, Bischoff-Ferrari HA, Frazier L, Willett WC. **Milk consumption** during teenage years and risk of hip fractures in older adults [online November 18, 2013]. *JAMA Pediatr*. doi:10.1001/jamapediatrics.2013.3821.

Fitzgerald KC, Munger KL, Köcher K, et al. Association of Vitamin D Levels With **Multiple Sclerosis** Activity and Progression in Patients Receiving Interferon Beta-1b. *JAMA Neurol*. 2015 Oct 12;1-8.

Gallagher JC, Yalamanchili V, Smith LM. The effect of **vitamin D on calcium absorption** in older women. *J Clin Endocrinol Metab*. 2012 Oct;97(10):3550-6.

Gallagher JC, Smith LM, Yalamanchili V. Incidence of **hypercalcaemia** and **hypercalcaemia** during vitamin D and calcium supplementation in older women. *Menopause*. 2014 Jun 16.

Gallo S, Comeau K, Vanstone C, et al. Effect of different dosages of oral vitamin D supplementation on vitamin D status in healthy, **breastfed infants**: a randomized trial. *JAMA*. 2013;309(17):1785-1792.

Gelfand JM, Cree BA, McElroy J, et al. **Vitamin D** in African Americans with **multiple sclerosis**. *Neurology*. 2011 May 24;76(21):1824-30.

Ginde AA, Blatchford P, Breese K, et al. High-Dose Monthly Vitamin D for Prevention of **Acute Respiratory Infection** in Older Long-Term Care Residents: A Randomized Clinical Trial. *J Am Geriatr Soc*. 2016 Nov 16. (reduced acute respiratory infection but higher rate of falls)

Golden NH, Abrams SA; Committee on Nutrition; **Optimizing bone health in children and adolescents**. *Pediatrics*. 2014 Oct;134(4):e1229-43.

Goodall EC, Granados AC, Luinstra K, et al. Vitamin D3 and **gargling for the prevention of upper respiratory tract infections**: a randomized controlled trial. *BMC Infect Dis*. 2014 May 19;14(1):273.

Goswami R, Vatsa M, Sreenivas V, et al. **Skeletal muscle strength** in young Asian Indian females after vitamin D and calcium supplementation: a double-blind randomized controlled clinical trial. *J Clin Endocrinol Metab*. 2012 Dec;97(12):4709-16.

Grant CC, Stewart AW, Scragg R, et al. **Vitamin D During Pregnancy and Infancy** and Infant Serum 25-Hydroxyvitamin D Concentration. *Pediatrics*. 2013 Dec 16

Hansen KE, Johnson RE, Chambers KR, et al. Treatment of **Vitamin D Insufficiency in Postmenopausal Women**: A Randomized Clinical Trial. *JAMA Intern Med*. 2015 Aug 3.

Health Canada. Eating well with Canada's food guide [Internet]. [Ottawa]: Health Canada. 2007 [cited: 2009 Sep 25]. 6 p. Available from: http://www.hc-sc.gc.ca/fn-an/alt_formats/hpbp-dgpsa/pdf/food-guide-aliment/print_eatwell_bienmang-eng.pdf

Heaney RP et al. Vitamin D3 is more potent than vitamin D2 in humans. *J Clin Endocrinol Metab* 2011 Mar; 96:E447.

Holick Michael F., Binkley Neil C., Bischoff-Ferrari Heike A., et al. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an **Endocrine Society** Clinical Practice Guideline *JCEM* 2011 jc.2011-0385.

Hollis BW, Wagner CL, Howard CR, et al. **Maternal versus infant vitamin D supplementation during lactation**: a randomized controlled trial. *Pediatrics*. 2015;136(4):625-634

Houston DK, Toozie JA, et al. Delivery of a Vitamin D Intervention in **Homebound Older Adults Using a Meals-on-Wheels Program**: A Pilot Study. *J Am Geriatr Soc*. 2015 Aug 16.

IOM (Institute of Medicine): Dietary Reference Intakes for Calcium and Vitamin D Nov,2010.
<http://www.iom.edu/~media/Files/Report%20Files/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Vitamin%20D%20and%20Calcium%202010%20Report%20Brief.pdf>

Jacobsen RB, Hronek BW, Schmidt GA, Schilling ML. **Hypervitaminosis D Associated with a Vitamin D Dispensing Error** (October). *Ann Pharmacother*. 2011 Sep 13.

Javed A, Kullo IJ, Babu Balagopal P, et al. Effect of vitamin D(3) **treatment on endothelial function in obese adolescents**. *Pediatr Obes*. 2015 Aug 14.

Jelinek GA, Marck CH, Weiland TJ, et al. Latitude, sun exposure and vitamin D supplementation: associations with quality of life and disease outcomes in a large international cohort of people with **multiple sclerosis**. *BMC Neurol*. 2015 Aug 5;15:132.

Jim X, Jones G, Cicuttini F, et al. Effect of Vitamin D Supplementation on **Tibial Cartilage Volume and Knee Pain** Among Patients With Symptomatic Knee Osteoarthritis: A Randomized Clinical Trial. *JAMA*. 2016 Mar 8;315(10):1005-13.

Kakigi CL, Singh K, Wang SY, et al. Self-reported **Calcium Supplementation and Age-Related Macular Degeneration**. *JAMA Ophthalmol*. 2015 Jul 1;133(7):746-54.

Kara C, Gunindi F, Ustyoal A, Aydin M. **Vitamin D intoxication due to an erroneously manufactured dietary supplement** in seven children. *Pediatrics*. 2014 Jan;133(1):e240-4.

Kashihara AK, Singh RJ, Noymer A. Vitamin D (25OHD) Serum **Seasonality** in the United States. *PLoS One*. 2013 Jun 21;8(6):e65785.

Kjærsgaard M, Waterloo K, Wang CE, et al. Effect of vitamin D supplement on **depression** scores in people with low levels of serum 25-hydroxyvitamin D: nested case-control study and randomised clinical trial. *Br J Psychiatry*. 2012 Jul 12.

Kojima G, Bell C, Abbott RD, et al. Low Dietary Vitamin D Predicts 34-Year Incident **Stroke**: The Honolulu Heart Program. *Stroke*. 2012 May 24.

Kumar Geeta Trilok, Sachdev Harshpal Singh, Chellani Harish, et al. Effect of weekly vitamin D supplements on mortality, morbidity, and growth of low birthweight term infants in India up to age 6 months: randomised controlled trial. *BMJ* 2011;342:doi:10.1136/bmj.d2975 (Published 31 May 2011)

Kunisaki KM, Niewoehner DE, Connert JE; COPD Clinical Research Network. Vitamin D levels and risk of acute exacerbations of **chronic obstructive pulmonary disease**: a prospective cohort study. *Am J Respir Crit Care Med* 2012;185:286-290.

Laird E, McNulty H, Ward M. Vitamin D deficiency is associated with **inflammation** in older Irish adults. *J Clin Endocrinol Metab* 2014.

Lasso A, Catalano A, Benavenga S. Improvement of **primary dysmenorrhea** caused by a single oral dose (300,000 IU) of vitamin D: results of a randomized, doubleblind, placebo-controlled study. *Arch Intern Med*. 2012;172(4):366-367.

Laurent MR, Gielen E, Pauwels S, et al. Hypervitaminosis D Associated With Tanning Bed Use: A Case Report. *Ann Intern Med*. 2017 Jan 17;166(2):155-156.

Laursen JH, Sondergaard HB, Sorensen PS, et al. Association between age at onset of **multiple sclerosis** and vitamin D level-related factors. *Neurology*. 2016 Jan 5;86(1):88-93.

Lavie CJ, Dimiccolantonio JJ, Milani RV, O'Keefe JH. Vitamin D and cardiovascular (atorvastatin myalgias) health. *Circulation*. 2013 Nov 26;128(22):2404-6.

Lawlor DA, Wills AK, et al. Association of maternal vitamin D status during **pregnancy with bone-mineral content** in offspring: a prospective cohort study. *Lancet* 2013; online March 19.

Leblanc ES, Perrin N, Johnson JD, et al. Over-the-Counter and **Compounded Vitamin D: Is Potency What We Expect?** *JAMA Intern Med*. 2013 Feb 11:1-2.

LeBlanc ES, Zakher B, Daeges M, et al. **Screening for Vitamin D Deficiency**: A Systematic Review for the U.S. Preventive Services Task Force. (USPSTF) *Ann Intern Med*. 2014 Nov 25.

Lee GJ, Birken CS, Parkin PC, et al; for the **TARGet Kids!** Collaboration. **Consumption of non-cow's milk beverages** and serum vitamin D levels in early childhood. *CMAJ*. 2014 Oct 20.

LeFevre ML. **Screening for Vitamin D Deficiency** in Adults: U.S. Preventive Services Task Force Recommendation Statement. (USPSTF) *Ann Intern Med*. 2014 Nov 25.

Lehouck A, Mathieu C, Carremans C, Baekke F, Verhaegen J, Van Eldere J, et al. High doses of vitamin D to reduce exacerbations in **chronic obstructive pulmonary disease**. A randomized trial. *Ann Intern Med*. 2012;156:105-14.

Lima GL, Paupitz J, Aikawa NE, et al. Vitamin D Supplementation in Adolescents and Young Adults With **Juvenile Systemic Lupus Erythematosus** for Improvement in Disease Activity and Fatigue Scores: A Randomized, Double-Blind, Placebo-Controlled Trial. *Arthritis Care Res (Hoboken)*. 2016 Jan;68(1):91-8.

Lindblad AJ, Garrison S, McCormack J. **Testing vitamin D levels**. *Can Fam Physician*. 2014 Apr;60(4):351.

Litonjua AA, Carey VJ, Laranjo N, et al. Effect of prenatal supplementation with vitamin D on **asthma or recurrent wheezing** in offspring by age 3 years: the VDAART randomized clinical trial. *JAMA*. doi:10.1001/jama.2015.18589.

Littlejohns TJ, Henley WE, Lang IA, et al. Vitamin D and the **risk of dementia and Alzheimer disease**. *Neurology*. 2014 Sep 2;83(10):920-8.

Manaseki-Holland S, Maroof Z, Bruce J, et al. Effect on the incidence of **pneumonia** of vitamin D supplementation by quarterly bolus dose to infants in Kabul: a randomised controlled superiority trial. *Lancet*. 2012 Apr 14;379(9824):1419-27.

Manson JE. Vitamin D and the heart: Why we need large-scale clinical trials (**VITAL**). *Cleveland Clinic Journal of Medicine* 2010; 77(12):903-910; doi:10.3949/ccjm.77gr.10004

Manson JoAnn E, Mayne Susan T, Clinton Steven K, Vitamin D and **Prevention of Cancer** — Ready for Prime Time? March 23, 2011 (10.1056/NEJMp1102022)

Manson JE, Brannon PM, Rosen CJ, et al. Vitamin D Deficiency - **Is There Really a Pandemic?** *N Engl J Med*. 2016 Nov 10;375(19):1817-1820.

Marcus JF, Shalev SM, Harris CA, et al. **Severe hypercalcaemia following vitamin D supplementation** in a patient with multiple sclerosis: a note of caution. *Arch Neurol*. 2012 Jan;69(1):129-32.

Martineau AR, MacLaughlin BD, Hooper RL, et al. Double-blind randomised placebo-controlled trial of bolus-dose vitamin D3 supplementation in adults with **asthma (VIDIAS)**. *Thorax*. 2015 Feb 27. pii: thoraxjnl-2014-206449.

Martineau AR, Hanifa Y, Witt KD, et al. Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of **acute respiratory infection** in older adults and their carers (**ViDiFlu**). *Thorax*. 2015 Jun 10.

Meyer HE, Holvik K, Lips P. Should vitamin D supplements be recommended to **prevent chronic diseases**? *BMJ*. 2015 Jan 29;350:h321.

McAlindon T, LaValley M, Schneider E, et al. Effect of vitamin D supplementation on **progression of knee pain and cartilage volume loss** in patients with symptomatic osteoarthritis: a randomized controlled trial. *JAMA*. 2013 Jan 9;309(2):155-62.

McGreedy C, Williams D. New insights about vitamin D and cardiovascular disease: a narrative review. *Ann Intern Med*. 2011 Dec 20;155(12):820-6.

McNally JD, Iliriani K, Popsupap S, et al. Rapid **Normalization of Vitamin D Levels**: A Meta-Analysis. *Pediatrics*. 2015 Jan;135(1):e152-e166.

Mergenhagen K, Ott M, Heckman K, et al. Low Vitamin D as a Risk Factor for the Development of **Myalgia in Patients Taking High-Dose Simvastatin**: A Retrospective Review. *Clin Ther*. 2014 Apr 14.

Michael YL, Whitlock EP, Lin JS, Fu R, O'Connor EA, Gold R. Primary care-relevant interventions to prevent falling in older adults: a systematic evidence review for the u.s. Preventive services task force (**USPSTF**). *Ann Intern Med*. 2010 Dec 21;153(12):815-25.

Miller JW, Harvey DJ, Beckett LA, et al. Vitamin D Status and Rates of **Cognitive Decline** in a Multiethnic Cohort of Older Adults. *JAMA Neurol*. 2015 Sep 14.

Mokry LE, Ross S, Ahmad OS, et al. **Vitamin D and Risk of Multiple Sclerosis**: A Mendelian Randomization Study. *PLoS Med*. 2015 Aug 25;12(8):e1001866.

Mokry LE, Ross S, Morris JA, et al. Genetically decreased vitamin D and **risk of Alzheimer disease**. *Neurology*. 2016 Dec 13;87(24):2567-2574

Munasinghe LL, Willows N, Yuan Y, et al. **Dietary reference intakes for vitamin D** based on the revised 2010 dietary guidelines are not being met by children in Alberta, Canada. *Nutr Res* 2015; online August 14, 2015.

Munger KL, Áivo J, Hongell K, et al. Vitamin D status during pregnancy and **risk of multiple sclerosis** in offspring of women in the Finnish Maternity Cohort [online March 7, 2016]. *JAMA Neurol*. doi:10.1001/jama.2015.4800.

Murad MH, Elamin KB, Abu Elnour NO, et al. Clinical review: The effect of **vitamin D on falls**: a systematic review and meta-analysis. *J Clin Endocrinol Metab*. 2011 Oct;96(10):2997-3006.

Murdoch DR, Slow S, Chambers ST, et al. Effect of vitamin D3 supplementation on **upper respiratory tract infections** in healthy adults: the VIDARIS randomized controlled trial. *JAMA*. 2012;308(13):1333-1339.

Muir SW, Montero-Ordaso M. Effect of vitamin D supplementation on **muscle strength, gait and balance** in older adults: a systematic review and meta-analysis. *J Am Geriatr Soc*. 2011 Dec;59(12):2291-300.

Nielson CM, Jones KS, Chun RF, et al; Osteoporotic Fractures in Men (MrOS) Research Group. **Role of Assay Type in Determining Free 25-Hydroxyvitamin D Levels** in Diverse Populations. *N Engl J Med*. 2016 Mar 23.

Newberry SJ, Chung M, Shekelle PG, et al. **Vitamin D and Calcium**: A Systematic Review of Health Outcomes (Update). Evidence Report/Technology Assessment No. 217. AHRQ Comparative Effectiveness Review. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Sept. Report No.: 14-E004-EF.

Noordam R, de Craen AJ, Pedram P, et al. Levels of 25-hydroxyvitamin D in familial **longevity**: the Leiden Longevity Study. *CMAJ*. 2012 Nov 5.

Oberhelman SS, Meekins ME, Fischer PR, et al. **Maternal vitamin D** supplementation to improve the vitamin D status of breast-fed infants: a randomized controlled trial. *Mayo Clin Proc*. 2013 Dec;88(12):1378-87.

OHTAC (Ontario Health Technology Advisory Committee) Recommendation June 2010 Clinical Utility of Vitamin D Testing. http://www.health.gov.on.ca/english/providers/program/ohatc/tech/recommend/rec_vitamin%20d_201002.pdf

Overton ET, Chan ES, Brown TT, et al. Vitamin D & Calcium Attenuate Bone Loss With **Antiretroviral Therapy** Initiation: A Randomized Trial. *Ann Intern Med*. 2015 Jun 16;162(12):815-24.

Pérez-López FR, Brincaat M, Erel CT, et al. **EMAS** position statement: Vitamin D and postmenopausal health. *Maturitas*. 2011 Nov 17.

Ponda MP, Huang X, Odeh MA, et al. Vitamin d may not improve **lipid levels**: a serial clinical laboratory data study. *Circulation*. 2012 Jul 17;126(3):270-7.

Powe CE, Evans MK, Wenger J, et al. **Vitamin D-binding protein** and vitamin D status of black Americans and white Americans. *N Engl J Med* 2013;369:1991-2000.

Rejnmark L, Avenell A, Masud T, et al. **Vitamin D with Calcium Reduces Mortality**: Patient Level Pooled Analysis of 70,528 Patients from Eight Major Vitamin D Trials. *J Clin Endocrinol Metab*. 2012 May 17.

Reid IR, Bolland MJ, Grey A. Effects of **vitamin D supplements on bone mineral density**: a systematic review and meta-analysis. *Lancet* 2013; online Oct 11.

Robinson-Cohen C, Hooftagle AN, Ix JH, et al. **Racial differences** in the association of serum 25-hydroxyvitamin D concentration with coronary heart disease events. *JAMA*. 2013;310(2):179-188.

Rosen Clifford J. **Vitamin D Insufficiency**. *N Engl J Med* 2011; 364:248-254.

Rossum RC, Espeland MA, Manson JE, et al. **Calcium and vitamin D** supplementation and **cognitive impairment** in the women's health initiative (**WHI**). *J Am Geriatr Soc*. 2012 Dec;60(12):2197-205.

Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose vitamin D3 and **mental well-being**: randomised controlled trial. *Br J Psychiatry*. 2011 May;198(5):357-64.

Schillingmann Karl P., Weber Stefanie, Goos Caroline, et al. **Mutations in CYP24A1 and Idiopathic Infantile Hypercalcemia**. June 15, 2011 (10.1056/NEJMoA1103864).

Schilling, Samantha, Wood, Joanne N., Levine, Michael A., et al. Vitamin D Status in **Abused and Nonabused Children** Younger Than 2 Years Old With Fractures. *Pediatrics* 2011 127: 835-841

Schnatz PF, Jiang X, Vila-Wright S, et al. **Calcium/vitamin D** supplementation, serum 25-hydroxyvitamin D concentrations, and cholesterol profiles in the Women's Health Initiative calcium/vitamin D randomized trial. *Menopause*. 2014 Mar 3.

Schöttker B, Jorde R, Peasey A, et al; Consortium on Health and Ageing: Network of Cohorts in Europe and the United States (**CHANCES**). **Vitamin D and mortality**: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. *BMJ*. 2014 Jun 17;348:g3656.

Schreuder F, Bernsen RM, van der Wouden JC. Vitamin d supplementation for nonspecific **musculoskeletal pain** in non-Western immigrants: a randomized controlled trial. *Ann Fam Med*. 2012 Nov;10(6):547-55.

Scragg R, Stewart AW, Waayer D, et al. Effect of monthly **high-dose (100,000 IU) vitamin D supplementation on cardiovascular disease** in the the Vitamin D Assessment Study: a randomized clinical trial [online Apr 5, 2017]. *JAMA Cardiol*. doi: 10.1001/jamacardio.2017.0175

Sethuraman G, Marwaha RK, Challa A, et al. Vitamin D: A New Promising Therapy for **Congenital Ichthyosis**. *Pediatrics*. 2016 Jan;137(1):1-5.

Shapses Sue A., Manson JoAnn E.. Vitamin D and **Prevention of Cardiovascular Disease and Diabetes**: Why the Evidence Falls Short . *JAMA*. 2011;305(24):2565-2566.

Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. *J Clin Epidemiol* 2009; 62(10):1013-20.

Singh P, Trivedi N. **Tanning beds** and hypervitaminosis d: a case report. *Ann Intern Med*. 2014 Jun 3;160(11):810-1.

Skrivsky AL, Kumar J, Abramowitz MK, et al. Association of **Glucocorticoid Use and Low 25-Hydroxyvitamin D Levels**: Results from the National Health and Nutrition Examination Survey (NHANES): 2001-2006. *J Clin Endocrinol Metab*. 2011 Sep 28.

Sohl E, van Schoor NM, de Jongh RT, et al. Vitamin D Status Is Associated With **Functional Limitations and Functional Decline** in Older Individuals. *J Clin Endocrinol Metab*. 2013 Jul 17

Soilu-Hänninen M, Aivo J, Lindström BM, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with **multiple sclerosis**. *J Neurol Neurosurg Psychiatry*. 2012 May;83(5):565-71.

Stein MS, Liu Y, Gray OM, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting **multiple sclerosis**. *Neurology* 2011;77:1611-1618.

Straube S, Derry S, Straube C, et al. Vitamin D for the treatment of **chronic painful conditions** in adults. *Cochrane Database Syst Rev*. 2015 May 6;CD007771. The evidence addressing the use of vitamin D for chronic pain now contains more than twice as many studies and participants than were included in the original version of this review. Based on this evidence, a large beneficial effect of vitamin D across different chronic painful conditions is unlikely. Whether vitamin D can have beneficial effects in specific chronic painful conditions needs further investigation.

Tang JY, Fu T, Leblanc E, et al. Calcium plus vitamin D supplementation and the risk of non-melanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial. *J Clin Oncol*. 2011 Aug 1;29(22):3078-84.

Tazzyman S, Richards N, Trueman AR, et al. Vitamin D associates with improved quality of life in participants with **irritable bowel syndrome**: outcomes from a pilot trial. *BMJ Open Gastroenterol*. 2015 Dec 21;2(1):e000052.

Thadhani R; Appelbaum E; Pritchett Y, et al. **Vitamin D** therapy (paricalcitol) and cardiac structure and function in patients with **chronic kidney disease**: The **PRIMO** randomized controlled trial. *JAMA* 2012; 307:674-684.

Theisen-Toupal J, Horowitz G, Breu A. Low yield of outpatient serum **folate testing**: eleven years of experience. *JAMA Intern Med*. 2014 Oct 1;174(10):1696-7.

Theodoratou E, Tzoulaki I, Lina Z, Ioannidis JP. **Vitamin D and multiple health outcomes**: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. *BMJ* 2014;348:g2035.

Thorand B, Zierer A, Huth C, et al. Effect of Serum 25-Hydroxyvitamin D on **Risk for Type 2 Diabetes** May Be Partially Mediated by Subclinical Inflammation: Results from the MONICA/KORA Augsburg study. *Diabetes Care*. 2011 Oct;34(10):2320-2.

Toffanello ED, Coin A, Perissinotto E, et al. **Vitamin D deficiency predicts cognitive decline** in older men and women: The Pro.V.A. Study. *Neurology*. 2014 Dec 9;83(24):2292-8.

Turner AN, Carr Reese P, Fields KS, et al. A blinded, randomized controlled trial of high-dose **vitamin D** supplementation to reduce recurrence of **bacterial vaginosis**. *Am J Obstet Gynecol*. 2014 Nov;211(5):479.e1-479.e13.

Vanstone M, Oberfield S, Shader L, et al. **Hypercalcemia** in Children Receiving Pharmacologic Doses of Vitamin D. *Pediatrics* 2012;129:e1060-e106.

Vimalaswaran KS, Cavardino A, Berry DJ, et al. Association of vitamin D status with **arterial blood pressure and hypertension risk**: A Mendelian randomisation study. *Lancet Diabetes Endocrinol* 2014.

Wang L, Manson JE, Song Y, Sesso HD. Systematic review: vitamin D and calcium supplementation in **prevention of cardiovascular events**. *Ann Intern Med*. 2010;152(5):315-323.

Welles CC, Whooley MA, Karumanchi SA, et al. Vitamin D deficiency and **cardiovascular events in patients with coronary heart disease**: data from the heart and soul study. *Am J Epidemiol*. 2014 Jun 1;179(11):1279-87.

Wepner F, Scheuer R, Schuetz-Wieser B, et al. Effects of vitamin D on patients with **fibromyalgia** syndrome: A randomized placebo-controlled trial. *Pain*. 2014 Feb;155(2):261-8

West NE, Lechtzin N, Merlo CA, et al. Appropriate goal level for 25-hydroxyvitamin D in **cystic fibrosis**. *Chest*. 2011 Aug;140(2):469-74.

Whitehouse AJ, Holt BJ, Serralha M et al. Maternal Serum Vitamin D Levels During Pregnancy and **Offspring Neurocognitive** Development. *Pediatrics*. 2012 Feb 13

Wingate KE, Jacobson K, Issenman R, et al. **25-Hydroxyvitamin D** Concentrations in Children with Crohn's Disease Supplemented with Either **2000 or 400 IU Daily** for 6 Months: A Randomized Controlled Study. *J Pediatr*. 2014 Jan 11

Winzenberg Tania, Powell Sandi, Shaw Kelly Anne, et al. Effects of vitamin D supplementation on bone density in healthy **children**: systematic review and meta-analysis. *BMJ* 2011;342:doi:10.1136/bmj.c7254 (Published 25 January 2011).

Witham MD, Price RJG, Struthers AD, et al. Cholecalciferol treatment to reduce **blood pressure** in older patients with isolated systolic hypertension. The **VitDISH** randomized controlled trial. *JAMA Intern Med* 2013.

Witte KK, Byrom R, Gierula J, et al. Effects of vitamin D on **cardiac function** in patients with chronic HF: The **VINDICATE** Study. *J Am Coll Cardiol* 2016.

Ye Z, Sharp SJ, Burgess S, et al; InterAct Consortium, Langenberg C, Wareham NJ, Forouhi NG. Association between **circulating 25-hydroxyvitamin D and incident type 2 diabetes**: a mendelian randomization study. *Lancet Diabetes Endocrinol*. 2014 Sep 30.

³⁵ Autier P, Gandini S. Vitamin D Supplementation and Total Mortality: A Meta-analysis of Randomized Controlled Trials. *Arch Intern Med*. 2007 Sep 10;167(16):1730-7

³⁶ Arreín K, Schneid C, Holl A, et al. Effect of High-Dose Vitamin D3 on Hospital Length of Stay in Critically Ill Patients With Vitamin D Deficiency: The VITdAL-ICU Randomized Clinical Trial. *JAMA*. 2014 Oct 15;312(15):1520-1530.

³⁷ Atherton K, Berry DJ, Parsons T et al. Vitamin D and widespread pain in a white middle-aged British population : evidence from a cross-sectional population survey. *Ann Rheum Dis*. 2009 Jun;68(6):817-22. Epub 2008 Aug 12.

³⁸ Holick MF. Clinical efficacy of 1,25-dihydroxyvitamin D, and its analogues in the treatment of psoriasis. *Retinoids*1998;14:12-7.

³⁹ Kragballe K, Barnes L, Hamberg KJ, et al. Calcipotriol cream with or without concurrent topical corticosteroids in psoriasis : tolerability and efficacy. *Br J Dermatol*1998;139:649-54.

⁴⁰ Mason AR, Mason J, Cork M, Dooley G, Edwards G. Topical treatments for chronic plaque psoriasis. *Cochrane Database Syst Rev*. 2009 Apr 15;(2):CD005028